December 9, 2002

Results of Epratuzumab for non-Hodgkin’s lymphoma therapy presented at American Society of Hematology meeting

December 9, 2002

Immunomedics reports on new humanized antibody therapeutics at American Society of Hematology meeting

December 4, 2002

Immunomedics reviews progress at annual meeting of shareholders

November 11, 2002

Immunomedics reports fiscal first quarter 2003 results

October 25, 2002

Immunomedics select Ernst & Young to serve as independent auditors for fiscal year 2003

October 24, 2002

Immunomedics’ unlabeled CEA antibody inhibits human tumor growth and enhances effects of cancer drug

October 22, 2002

New patented method could overcome drug resistance in cancer and infectious diseases

October 16, 2002

Medix Biochemica licenses Immunomedics’ CEA antibody technology

October 14, 2002

Immunomedics advances intellectual property for lymphoma and other cancer therapies

October 1, 2002

Immunomedics awarded patents in U.S. and Australia for infectious disease therapy

August 12, 2002

Immunomedics advances intellectual property for lymphoma and other cancer therapies

July 19, 2002

Immunomedics granted Israeli patent on new biological drugs to overcome multidrug resistance

July 10, 2002

New Jersey district court rules that Immunomedics’ patent suit against Cytogen will continue

July 10, 2002

Daiichi licenses Immunomedics’ CEA antibody technology

July 2, 2002

Immunomedics wins infringement suit in Dutch appeals court

June 19, 2002

Immunomedics reports preclinical progress in breast cancer therapy at the Society of Nuclear Medicine meeting

June 17, 2002

Immunomedics reports clinical and preclinical progress of its products and technologies at the Society of Nuclear Medicine meeting

May 24, 2002

Immunomedics acquires Beckman Coulter’s share of IBC Pharmaceuticals

May 21, 2002

Advances in cancer therapy reported at American Society of Clinical Oncology meeting

May 20, 2002

Immunomedics announces additional interim results of Epratuzumab combination in treating non-Hodgkin’s lymphoma

May 17, 2002

Teva-Tuteur to market and distribute Immunomedics’ diagnostic imaging products in Latin America

May 14, 2002

Immunomedics awarded U.S. patent for new method of intraoperative, intravascular, and endoscopic detection and therapy of diverse diseases

May 8, 2002

Immunomedics reports fiscal third quarter 2002 results

May 2, 2002

Immunomedics appoints new executive vice president for research and development

April 30, 2002

Immunomedics awarded patents for abnormal organ and tissue therapy, and for new cardiovascular imaging agents

April 9, 2002

Immunomedics reports research progress at national cancer meeting

March 26, 2002

Immunomedics granted U.S. patent for improved, prodrug chemotherapy

March 25, 2002

Immunomedics appoints chief medical officer

March 7, 2002

Immunomedics gains approval recommendation for leukoscan in Australia

March 5, 2002

1 Immunomedics adopts new 2002 stockholders rights plan to replace existing 1998 rights plan

February 28, 2002

Encouraging Phase-II trial results in the therapy of advanced colorectal cancer patients published

February 1, 2002

Immunomedics reports fiscal second quarter 2002 results

January 14, 2002

Immunomedics to present at the Wachovia Securities Integrated Oncology Conference